Ryvu Therapeutics Restructures Operations to Extend Cash Runway, Prioritizes RVU120 Blood Cancer Program
Key Insights
Ryvu Therapeutics (search) announces strategic reorganization, reducing workforce by 30% while extending cash runway to H2 2026 with €46 million in current assets and €22 million in secured grant funding.
Company focuses resources on three ongoing Phase II trials of RVU120 in blood cancers, discontinuing new enrollment in RIVER-52 monotherapy study for AML and HR-MDS patients.
Development continues for novel ADC programs and precision medicine platform ONCO Prime, while maintaining partnerships with Menarini, BioNTech, and Exelixis.
Ryvu Therapeutics (search), a clinical-stage drug discovery and development company, has announced a strategic reorganization to optimize its resources and extend its cash runway through the second half of 2026. The restructuring comes as the company sharpens its focus on advancing its lead blood cancer program RVU120 and early-stage pipeline assets.
The Polish biotech will reduce its workforce by approximately 30%, bringing total employee count to around 200. The company currently holds approximately €46 million in cash and other financial assets, supplemented by €22 million in secured non-dilutive grant funding.
Strategic Focus on RVU120 Clinical Program
The company is prioritizing three Phase II clinical trials of RVU120, while strategically discontinuing new patient enrollment in one study. The ongoing trials include:
- RIVER-81: Combination therapy with venetoclax in acute myeloid leukemia (AML)
- POTAMI-61: Monotherapy and combination with ruxolitinib in myelofibrosis
- REMARK: Monotherapy in lower-risk myelodysplastic syndromes (LR-MDS)
The Phase II RIVER-52 study, investigating RVU120 monotherapy in AML and high-risk MDS patients, will stop enrolling new patients but continue treatment for currently enrolled participants. This decision follows recent data analysis and advisory board recommendations in February 2025.
"We remain focused on advancing our first-in-class clinical blood cancer program RVU120, as well as promising early-stage assets," stated Paweł Przewięźlikowski, Chief Executive Officer and largest shareholder of Ryvu. "Considering our cash position, revenue projections, cost structure and the demanding market environment, we decided to optimize expenses so that the company has sufficient cash runway to generate key data for RVU120 and the preclinical pipeline."
Advancing Early-Stage Programs and Partnerships
Ryvu continues to advance its preclinical portfolio through two main strategies:
-
ONCO Prime Platform: Development of novel small molecule precision medicines, including synthetic lethality targets, supported by a PLN 26 million grant from the Polish Agency for Enterprise Development.
-
Antibody-Drug Conjugates (ADCs): Focus on next-generation novel payloads, including the repositioning of their WRN program as an ADC payload. This research is backed by approximately PLN 13 million in grant funding.
The company maintains active partnerships with:
- Menarini: Phase II JASPIS-01 study of dapolsertib in DLBCL
- BioNTech: Multi-target research collaboration in small molecule immune modulators
- Exelixis: Development of ADCs with STING payloads
Clinical Development Timeline
RVU120's next data update is scheduled for Q2 2025, while RVU305, the company's PRMT5 inhibitor for solid tumors, is progressing through IND/CTA-enabling studies with expected completion in H2 2025.
The restructuring positions Ryvu to achieve significant clinical milestones while maintaining financial stability through key data readouts that could support future partnering opportunities or internal development programs.